Ps The plan that IRWD has followed in partnering with international drug companies in the development of Linzess is a virtual carbon copy of the plan that Medivation used in partnering with Astellas in developing Xtandi. That's worked out pretty well, I'd say,.
You say they sold the international rights for "a small royalty". They sold half the international rights - and the US rights - for substantial upfront payments and milestone payments. They get half the European and Mexican profits while their partners cover all of the developmental and marketing costs. In the case of the Chinese, Japanese, and other Asian markets, they get 50% of the profits, which eventually escalate to 55%. To this point, their partners have invested about $850 million in the development of Linzess.
Synergy is almost broke. They have about $80 million left and are burning through more than $25 million a quarter. They don't even have the cash to get to the end of the year, much less launch plecanatide, which will cost them at least an additional $200 milion in the initial year alone. Yeah, good luck, longs.
These Harvard guys are touchy. Maybe the Linzess rep parked in his space.
Well, we can debate the arcana of trials and statistics, but one wonders: Even before FDA approval, Ironwood had signed partnerships worldwide. If the plecanatide trials are so impressive, why have they never signed a partnership with anyone? Why, as I have asked before, has no one ever taken a nibble out of that luscious plecanatide pie?
I think that this quack and gia are just upset because Linda, the Lovely Linzess Lady, spurned their advances.
If you post verifiable facts and numbers here, they will be assailed as lies. If you post fantasies about $15 buyouts, you willbe commended for your financial acumen.
Just posting this again, rather than reconstruct the whole thing. A CIC drug which does not, at some dosage, produce diarrhea is like a nonflammable lighter fluid: very, very safe.
When will Allergan buy Synergy? When Donald Trump sees Ted Cruz drowning in the pool at Mar a Lago and jumps in to save him.
Bought more today at 10.39-10.40. Sold them at 10.75. If the market had held up, it would have gone to 11. Ironwood will be cash flow positive before plecanatide is approved.
When a stock pops at the open, then trades huge volume but is unable to advance beyond the initial pop, good sense would tell you that it is being sold into the heavy volume smokescreen. (i.e. The short position is back.)
They painted the tape @ 3.76 in the premarket. Then, in the first half hour of trading, they passed it back and forth, creating huge volume. But the price never really moved up, which demonstrated that they're exiting.
If you had been watching, you would realize that "indiansfans" is the antichrist to the always long and revered "indiansfan".
...which were often pooh-poohed by those who insisted that 20 or 25 was a more reasonable valuation? They remind me of the old story about the two Irishmen immigrating to America in the '40's. They get off the boat in New York City and walk out onto 12'th Avenue. A $5 bill comes blowing down the street and lands in front of them. One of them bends over to pick it up, when the other stops him: "Jasus, Pat, don't be fillin' yer pockets up with those - wait for the big bills."
One of the characteristic things about short squeezes is that they stop along the way to allow the recalcitrant shorts to double up. Thus it lingered at 10.50 and then again at 10.75. Let them get both hands and both feet into the tarbaby.
PS What the trading at the moment is telling you is that what's coming around the corner is not a buyout offer, but a secondary offering at ...let's guess 2.60. While you were all cheering the small gains over the past two sessions, the massive volumes showed that, once again, you were being duped.